Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Salestools Logo

Salestools

#1 AI-agent til salgsteams og Go-to-Market-teams. Sælg mere, hurtigere, med mindre indsats.

Produkt

  • AI-salgsagenter
  • Intent-data
  • Teknologidata
  • Besøgssporing
  • Co-Pilot
  • Socialt salg

Løsninger

  • Kundeservice
  • E-handel
  • SaaS
  • Enterprise
  • Lille virksomhed

Ressourcer

  • Rapporten
  • Dokumentation
  • API-reference
  • Hjælpecenter
  • Blog
  • Case-studier
  • Webinarer

Virksomhed

  • Om os
  • Karriere
  • Presse
  • Kontakt
  • Partnere

Vores lokationer

  • New York, HQ
  • Bukarest, AI-forskningslaboratorium
  • Zug, Schweiz

© 2026 Salestools. Alle rettigheder forbeholdes.

Datavilkår & sikkerhedPrivatlivspolitikServicevilkårAcceptable Use
Alle systemer operationelle
Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Back to Reports
Fundraising

Synthesia

Synthesia Raises $200M in Series D

London, UKOctober 31, 20252 min read
Employees
300+

Synthesia Raises $200M in Series D


Synthesia has successfully raised $200M in a Series D at a $4B valuation led by GV (Google Ventures), Kleiner Perkins, Accel.


Company Overview


Synthesia is a AI/ML company headquartered in London, UK, founded in 2017 with 300+ employees.


AI video generation platform creating professional videos with AI avatars and voiceovers


Fundraising Details


  • Amount Raised: $200M
  • Round Type: Series D
  • Valuation: $4B
  • Date: 2025-10-31
  • Investors: GV (Google Ventures), Kleiner Perkins, Accel

About Synthesia


AI video generation platform creating professional videos with AI avatars and voiceovers The company is positioned in the AI/ML sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: London, UK
  • Founded: 2017
  • Team Size: 300+
  • Industry: AI/ML

What This Means


This funding round demonstrates strong investor confidence in Synthesia's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The AI/ML sector continues to attract significant investment as companies innovate to meet evolving market demands. Synthesia's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $4B valuation marks an important milestone for Synthesia, positioning the company among notable players in the AI/ML industry.


Looking Ahead


With this new capital, Synthesia is well-positioned to execute on its growth strategy and continue building innovative solutions in the AI/ML space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2025-10-31. For more information about Synthesia, visit their headquarters at London, UK.

Company Info

Headquarters
London, UK
Founded
2017
Team Size
300+

Topics

Fundraising(2912)AI/ML(484)Series D(267)Synthesia

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free